Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Guggenheim

Deciphera Pharmaceuticals (NASDAQ:DCPH)‘s stock had its “neutral” rating reissued by analysts at Guggenheim in a research report issued on Tuesday, Benzinga reports.

A number of other analysts also recently issued reports on DCPH. Jonestrading reaffirmed a “hold” rating and set a $25.60 price target on shares of Deciphera Pharmaceuticals in a report on Monday. Barclays raised shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $9.00 to $26.00 in a research report on Tuesday. Jefferies Financial Group reissued a “hold” rating and set a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday. JMP Securities reaffirmed a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Wednesday, March 20th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $24.17.

Deciphera Pharmaceuticals Stock Up 0.4 %

Shares of DCPH opened at $25.36 on Tuesday. The stock has a market cap of $2.09 billion, a P/E ratio of -11.07 and a beta of 0.39. Deciphera Pharmaceuticals has a 52 week low of $9.90 and a 52 week high of $25.40. The business’s 50 day moving average price is $16.18 and its 200-day moving average price is $14.63.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter in the previous year, the business earned ($0.60) earnings per share. The company’s revenue was up 32.9% on a year-over-year basis. On average, equities analysts anticipate that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of DCPH. Capstone Investment Advisors LLC bought a new stake in Deciphera Pharmaceuticals during the 1st quarter worth approximately $353,000. China Universal Asset Management Co. Ltd. raised its position in shares of Deciphera Pharmaceuticals by 67.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,513 shares of the company’s stock valued at $244,000 after purchasing an additional 6,241 shares during the period. Diversified Trust Co raised its position in shares of Deciphera Pharmaceuticals by 6.5% during the 1st quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock valued at $201,000 after purchasing an additional 778 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the 1st quarter valued at $291,000. Finally, Fisher Asset Management LLC bought a new position in Deciphera Pharmaceuticals in the 4th quarter worth $1,006,000. 70.96% of the stock is currently owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.